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ABSTRACT
Outcomes of hematopoietic cell transplantation are steadily improving. New techniques have reduced trans-
plant toxicities, and there are new sources of hematopoietic stem cells from unrelated donors. In June 2007 the
Blood and Marrow Transplant Clinical Trials Network convened a State of the Science Symposium of more
than 200 participants in Ann Arbor to identify the most compelling clinical research opportunities in the field.
This report summarizes the symposium’s discussions and identifies eleven high priority clinical trials that the
network plans to pursue over the course of the next several years.
© 2007 American Society for Blood and Marrow Transplantation
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nNTRODUCTION
Over the past 20 years, the number of hemato-
oietic stem cell transplants (HSCTs) has increased
t a rate of 2000 transplants per year so that today
pproximately 50,000 transplants are performed an-
ually worldwide. Despite the increasing use of this
omplex and intensive therapy, very few patients
nter clinical trials. The reasons are multiple, and
nclude all the usual barriers to the conduct of
linical research in sick patient populations. In ad-
ition, obstacles to clinical trials of HSCT are am-
liﬁed by the limited number of patients per center
nd heterogeneity in risk factors, such as the type and
tage of primary diagnosis, the age of the donor and
ecipient, the type and source of donor stem cells,
nd transplant technique, among others. p
268In 2001, the National Heart, Lung, and Blood
nstitute (NHLBI) and the National Cancer Insti-
ute (NCI) chartered the Blood and Marrow Trans-
lantation Clinical Trials Network (BMT CTN) to
ddress these problems and conduct HSCT clinical
rials that would advance the standard of care for
ransplant patients. In preparation for this charter, a
tate of the Science Symposium (SOSS) was con-
ened, which deﬁned 6 key areas that would help
rame the scientiﬁc agenda of the BMT CTN: op-
imal graft source and composition, regimen related
oxicity, graft-versus-host disease (GVHD), infec-
ion and immune reconstitution, quality of life/late
ffects, and relapse of malignancy following HSCT.
he BMT CTN has now been operational for
early 6 years, with a total accrual of almost 2000
atients into trials. To frame the scientiﬁc agenda
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BMT CTN State of the Science Symposium 2007 1269or the next 5 years, the network planned a second
OSS organized in 12 committees. The initial area
f relapse of malignancy was expanded to 3 com-
ittees, including leukemia, lymphoma, and multi-
le myeloma, to better address the disease-speciﬁc
ssues inherent in these diagnoses. Committees in
ediatrics, nonmalignant diseases, cell and gene
herapy, and strategies for successful trial design
nd implementation were added.
To gain the widest perspectives possible, individ-
al members of the BMT CTN steering committee
ach participated in only 1 SOSS committee, and all
ommittees were composed primarily of individuals
utside the network leadership. In addition, members
f the NCI cooperative groups were included in all the
alignancy committees (leukemia, lymphoma, multi-
le myeloma). Intensive committee work began in
eptember 2006, and after multiple meetings, draft
eports from all 12 committees were reviewed be-
ore the symposium, by a panel of international
xperts who led the question periods during the
OSS in Ann Arbor. Where sufﬁcient preliminary
ata existed and the committee members reached
onsensus, they proposed 1 or more trials, pre-
ented here with a background, hypothesis, design,
nd feasibility considerations. In the absence of suf-
cient data or consensus, a more general strategy
as proposed. This article summarizes the discus-
ion of all the committees, and concludes with a list
f the trials that were endorsed most enthusiasti-
ally by the Symposium leadership.
URRENT BMT CTN TRIALS
101 Phase III randomized comparison of
ﬂuconazole versus voriconazole for the
prevention of invasive fungal infections after
allogeneic HSCT.
102 Phase III biologic assignment comparison of
double autologous HSCT versus tandem
autologous/allogeneic HSCT for patients
with multiple myeloma.
201 Phase III randomized comparison of
granulocyte-colony stimulating factors (G-
CSF) mobilized peripheral blood stem cells
(PBSC) versus bone marrow from HLA-
identical unrelated donors.
301 Phase II trial of ﬂudarabine-based
conditioning for allogeneic HSCT from
HLA-identical unrelated donors in severe
aplastic anemia (AA).
302 Phase II randomized comparison of
etanercept, mycophenolate mofetil (MMF),
denileukin diftitox, and pentostatin, in
combination with corticosteroids as initial
systemic treatment of acute GVHD. u303 Phase II trial of HLA identical, CD34
enriched, T cell-depleted, peripheral blood
HSCT for patients with acute myelogenous
leukemia (AML) in ﬁrst or second remission.
401 Phase III randomized comparison of rituxan/
beam versus bexxar/beam with autologous
HSCT for diffuse large B cell lymphoma.
402 A Phase III randomized comparison of
tacrolimus/sirolimus versus
tacrolimus/methotrexate (MTX) as GVHD
prophylaxis after HLA-identical related
donor HSCT.
403 Phase III randomized comparison of
etanercept versus placebo for treatment of
idiopathic pneumonia syndrome.
501 Phase III randomized comparison of single
versus double umbilical cord blood (UCB)
transplantation in pediatric patients with
high-risk leukemia and myelodysplasia.
502 Phase II study of nonmyeloablative
allogeneic HSCT for older patients with
AML in complete remission (CR).
601 Phase II study of nonmyeloablative unrelated
donor HSCT for children with severe sickle
cell disease.
OMMITTEE 1. OPTIMAL DONOR AND GRAFT
OURCE
urrent State of the Science
HSCTs from other than HLA-identical siblings
re associated with greater risks of graft rejection,
VHD, infection, and death. Mobilized blood is now
he most frequent source of stem cells from volun-
eers, and an ongoing BMT CTN Phase III trial is
omparing marrow and mobilized blood cells from
dult volunteers.
Phase II BMT CTN trials of reduced intensity
RIC) regimens in older patients testing double unit
ord blood grafts, and T-replete haplotype-mis-
atched related transplant with postgrafting cyclo-
hosphamide are in development. We believe the
ollowing 2 trials represent important research op-
ortunities.
rial 1. Unrelated Donor Transplantation versus
hemotherapy for High-Risk AML
Background and Hypothesis. AML is the primary
ndication for unrelated transplantation, usually after
hemotherapy failure. Randomized trials and 2 meta-
nalyses have shown that HLA-identical sibling grafts
mprove survival compared to chemotherapy [1,2].
urvival of AML patients with high-risk cytogenetics
ransplanted in ﬁrst remission is similar (30%),
hether the donors are HLA-identical siblings or un-
elated volunteers [3]. We will test the hypothesis that
nrelated donor transplantation soon after induction
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J.L.M. Ferrara et al.1270hemotherapy improves survival of patients with AML
ompared to treatment with best chemotherapy.
Trial Design and Feasibility. We propose a Phase III
rial comparing unrelated donor transplantation to
hemotherapy for AML patients with high-risk cyto-
enetics, aged 18-60 years, in collaboration with U.S.
nd European cooperative groups. At diagnosis, pa-
ients will have cytogenetics and HLA typing per-
ormed, siblings will be HLA typed, and unrelated
onor searches of patients with AML coordinated as
eeded. The treatment arm will be allocated accord-
ng to whether a HLA-matched sibling or volunteer
onor is identiﬁed. In 225 patients having an unre-
ated donor and 122 have no donor, there will be an
0% power to detect a 15% difference in 3-year sur-
ival between the treatments, anticipating 30% versus
5% patients alive. A total of 2000 AML patients is
equired: 30% (600) will have high-risk cytogenetics,
0% (480) will survive 6 months, and 75% (360) will
ave no HLA-identical sibling. Challenges are the
ooperation between groups to enroll 600 AML pa-
ients with high-risk cytogenetics over a reasonable
ime, and the coordination of timely HLA typing and
donor search.
rial 2. Cord Blood versus Adult Stem Cell
ources from Unrelated Donor
Background and Hypothesis. Both cell dose and HLA
ismatching are barriers to cord blood engraftment.
reliminary data indicate that transplantation of 2
artially HLA-matched cords overcome graft resis-
ance in adults and reach similar survival as adult
arrow grafts [4,5]. We will test the hypothesis that if
he cell dose barrier to engraftment can be overcome,
ord blood will be safer than adult stem cell sources.
Trial Design and Feasibility. We propose a random-
zed Phase III study of 8/8 HLA-A, -B, -C, -DRB1
atched volunteer and a 6 of 6 or 5 of 6 cord blood
raft consisting of 1 or 2 units (depending on the
vailable dose) or a 7 of 8 volunteer and a double unit
of 6 cord blood graft. The primary endpoint is
-year survival. A sample size of 732 patients will have
n 80% power to detect a difference of 10% between
he 2 graft sources. Cord blood use for adults will
ikely increase and by the time an ongoing Phase II
enter for International Blood and Marrow Trans-
lant Research (CIBMTR) trial is completed, a sufﬁ-
ient number of adult patients will be referred for cord
lood transplantation to make a Phase III trial feasi-
le.
iscussion Summary
There was high enthusiasm at the meeting for the
rial of Unrelated Donor Transplant versus Nontrans-
lant Chemotherapy for High Risk AML that was
resented by both committees 1 and 7. The Phase III mrial of cord blood versus adult stem cells was deferred
ontingent upon successful completion of the CIB-
TR double unit cord blood trial.
OMMITTEE 2. REGIMEN RELATED TOXICITY
urrent State of the Science
HSCT is associated with signiﬁcant nonrelapse
ortality (NRM) mainly from GVHD and regimen-
elated toxicities (RRT). Mucositis, veno-occlusive
isease (VOD) of the liver (also known as sinusoidal
bstruction syndrome) and pulmonary toxicity (PT)
ccur in 5%-10% of HSCT patients following my-
loablative conditioning and account for approxi-
ately 30% of deaths. The ability to predict RRT risk
s poor, and better prediction should improve out-
ome [6-8]. Efforts to reduce RRT have focused on
educing regimen intensity rather than direct preven-
ion or early treatments, although a Phase III BMT
TN trial using etanercept to treat PT is about to
pen [9].
rial 1. Genetic Predictors for Risk of
egimen-Related Organ Toxicities after HSCT
Background and Hypothesis. Variability in the ex-
ression of genes associated with mechanistic path-
ays of RRT has not been extensively studied. Prior
tudies have validated the concept of mechanistically
ased genetic risk prediction on only a small set of
peciﬁc genes and polymorphisms [6,10,11]. In addi-
ion, because it is likely that cooperative genes inﬂu-
nce outcome, single nucleotide polymorphisms
SNPs) of a single gene fail to take into account the
ultigenetic nature and associations of complex traits.
enome-wide genotyping using new Bayesian net-
ork statistical approaches are now available, and can
e used on large datasets to deﬁne mechanistic asso-
iations [12,13]. We will test the hypothesis that risks
or RRT are largely determined by genetic factors,
nd that these risks can be predicted by individual
enotyping using SNPs analysis.
Trial Design and Feasibility. Patients enrolled on
MT CTN 0101 have all undergone myeloablative
llogeneic HSCT in the last 3 years with comprehen-
ive clinical data and banked samples of DNA avail-
ble. Genome-wide genotyping of a subset of these
amples will be conducted. A prognostic model for
oxicities will be generated and validated in a prospec-
ive population. Information gained from patterns of
NP associations should lead to potential targets for
herapeutic intervention. Genotyping of 200 samples
anked from BMT CTN 0101 patients with RRT will
e compared to 100 samples from controls without
rgan toxicity. The GeneChip® Human Mapping
00K Array Set will be used to develop a prognostic
odel using Bayesware Discoverer software, and will
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BMT CTN State of the Science Symposium 2007 1271e validated with a second sample of 200 patients
reated in subsequent BMT CTN trials.
rial 2. Pulmonary Function Monitoring and Early
valuation of Pulmonary Toxicity after Allogeneic
SCT
Background and Hypothesis. Pulmonary toxins are
ommonly used in HSCT regimens (eg, busulfan,
armustine, and radiation) and pulmonary complica-
ions remain a cause of HSCT RRT. Posttransplant
ulmonary function test (PFT) monitoring is not
tandardized, and detection of pulmonary abnormali-
ies often occurs after toxicity is irreversible. Earlier
esting may lead to earlier and more targeted therapy.
e will test the hypothesis that scheduled PFT with
arly CT scanning and bronchoscopy will result in
arlier detection of pulmonary toxicity and lead to
herapies.
Trial Design and Feasibility. Patients undergoing
yeloablative or reduced-intensity allogeneic HSCT
ill undergo PFTs (spirometry and diffusing capacity)
retransplant and monthly for 6 months and then
very 2 months until 1 year. A signiﬁcant decline in
EV1 or diffusing capacity or an increase in residual
olume will initiate radiology (chest X-ray and chest
T), bronchoscopy, with bronchoalvealor lavage, and
iopsy with concurrent blood samples for cytokine
nalysis. The incidence of pulmonary toxicities is ex-
ected to be 5%-10%; 300 patients would need to be
nrolled to obtain 20 affected patients. Estimated ac-
rual of over 600 patients in BMT CTN studies
ithin the next 4 years suggest this is feasible.
iscussion Summary
Discussion concerning the genotyping proposal to
nderstand the intra-patient variability of RRT was
ery positive. A Biomarkers Committee will be
ormed to further consider the best use of DNA and
ellular and serum samples collected during BMT
TN trials to answer this and other correlative ques-
ions. The discussion of the pulmonary toxicity mon-
toring project concluded that a ﬁnal trial design
hould await availability of results of ongoing pilot
tudies from University of Washington, Seattle, and
he University of Michigan.
OMMITTEE 3. GVHD
urrent State of the Science
The ability to make HSCT more effective will
equire improved control of both GVHD and graft-
ersus-leukemia effects (GVL). The critical criteria
or successful HSCT are the reduction of the morbid-
ty of GVHD while maintaining an effective GVL
esponse and allowing effective immune recovery.
ritical to the mission of the BMT CTN are studies df both prevention and therapy of acute and chronic
VHD (aGVHD, cGVHD). GVHD prophylaxis
ypically depends on a calcineurin inhibitor (CNI)
ased on studies from the 1980s [14,15]. Cellular
ngineering approaches focusing on depletion of T
ells from the stem cell product have not been con-
istently successful and have not improved survival.
wo active prophylaxis trials, BMT CTN 0303 and
MT CTN 0402, address important issues in
atched related donors. Primary therapy for GVHD
s currently under investigation in BMT CTN 0302.
rials are now in development to explore alternative
ources of hematopoietic stem cells, including hap-
oidentical donors and 2 UCB units. Trials will be
eeded to progress rationally from the current BMT
TN portfolio to the next series of Phase III trials.
wo approaches should be helpful in moving forward:
1) approaches to improve our understanding and
reatment of cGVHD, and (2) Phase II trials of
VHD prophylaxis.
rial 1. A Randomized Phase II Trial for High-Risk
GVHD
Background and Hypothesis. Evolving understanding
f immunologic control mechanisms suggests that
anipulation of cellular populations other than con-
entional T cells, either in vivo or ex vivo, may be
eneﬁcial. CNI inhibit both regulatory T cells (Treg)
nd conventional T cells and may interfere with thy-
ic function [16,17]. It is possible that observed rates
f cGVHD relate to the inability of CNI to induce
ong-term tolerance [18-20]. Augmentation of natural
r inducible Treg number or function may mitigate
VHD and facilitate immune competence while
aintaining GVL [21]. Several approaches to aug-
ent Treg numbers or activity are feasible. Sirolimus
ased, CNI-free regimens (eg, sirolimus/MMF) may
oster Treg whereas inhibiting effector T cells. In
ouse models GVHD is prevented, whereas GVL is
aintained [21]. Extracorporeal photopheresis (ECP)
lso may enhance Treg numbers while modulating
PC function. ECP could be used as prescriptive
herapy for both aGVHD and cGVHD [22-24], al-
hough clinical data for this approach is minimal. We
ill test the hypothesis that treatment without cal-
ineurin inhibitors will improve outcomes for high
isk cGVHD patients.
Trial Design and Feasibility. Criteria to deﬁne high-
isk cGVHD are under discussion. A 3-arm trial
ould be most straight forward, but practices regard-
ng ECP vary widely between centers, and this lack of
quipoise may favor 2 parallel Phase II studies with a
ommon comparator arm, with all patients receiving
irolimus. A major limitation in the design of cGVHD
rials is our primitive understanding of the pathophys-
ology of cGVHD. In these trials, prospective clinical
ata matched to biomarker studies should be col-
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J.L.M. Ferrara et al.1272ected. Prospective clinical trials must include detailed
ultimodality assessment of symptoms, functions, and
linical status to determine which manifestations are
est amenable to reversal and best correlate with re-
uction in NRM. Comprehensive biomarker analysis
n cGVHD should guide further exploratory and ther-
peutic studies [25]. We recommend the initiation of
etailed, prospective assessments of biomarkers of
GVHD risk and relevant modulating factors. Studies
hould target the development of cGVHD, resistance
o therapy, and relapse.
Strategy 2. Animal studies show that depletion of
ost antigen presenting cells (APCs) pre-HSCT or
onor plus host APCs after HSCT may prevent
VHD [26,27]. Some single-center Phase II studies
re currently exploring this approach to GVHD
rophylaxis.
Strategy 3. Limited data suggest that enhance-
ent of natural killer T cell (NKT) populations may
imit GVHD, whereas sparing GVL [28]. Either en-
ogenous NKT cell function could be enhanced or ex
ivo selection and infusion of NK cells could be pur-
ued. Alternatively, KIR selection strategies permis-
ive of NK alloreactivity may limit GVHD.
iscussion Summary
Considerable interest focused on the need for
ore preclinical work before we embark on trials
esigned to enhance Treg activity or modulation of
PC numbers and function. In addition, the discus-
ion identiﬁed the need for better understanding of
he presentation of early-stage GVHD and the re-
ponse of early-stage GVHD to therapy. Future trials
ill address these considerations by building on the
urrent BMT CTN portfolio.
OMMITTEE 4. INFECTION AND IMMUNE
ECONSTITUTION
urrent State of the Science
Delays in immune reconstitution or suboptimal
ecovery of immune function place the HSCT patient
t prolonged risk for serious infection. The goal of any
trategy to boost immune reconstitution is to prevent
erious infection or reduce the interval of risk. The
MT CTN conducted a Phase III trial of antifungal
rophylaxis in 600 allogeneic transplant patients com-
aring voriconazole to ﬂuconazole with intensive ga-
actomannan monitoring to determine the 6-month
urvival free of invasive fungal infection as the primary
ndpoint. Analysis of results will be known in late
007. The BMT CTN is also conducting a prospec-
ive immune assessment using a limited number of
mmune assays as part of a Phase III trial in matched
nrelated donor transplant recipients comparing pe- wipheral blood to bone marrow as stem cell graft
ource. This trial has reached the halfway point in
ccrual; results will not be known for several years.
Strategy 1. Detailed, Multicenter Longitudinal
tudies of Functional Immune Reconstitution. A number
f single-center studies of global and pathogen-spe-
iﬁc immune responses over time have been per-
ormed. Knowledge about the pace and extent of cel-
ular and humoral immune reconstitution and
nformation about factors that inﬂuence the pace of
ecovery is incomplete. Moreover, changes in trans-
lant practices have occurred and considerable gaps in
nowledge exist regarding the inﬂuences of several
ey variables, including the donor immune status
rior to donation, the use of particular agents in the
reparative regimen, age-related thymic involution,
raft type, immunosuppressive regimens, and the type
f donor. Different assays at different centers and
ifferent mixtures of types of patients make generali-
ations from studies at single centers difﬁcult. Func-
ional assays that allow more in-depth evaluation of
mmune reconstitution is complicated by the lack of
nderstanding of standardized antigen preparations,
articularly for pathogens with large antigen proﬁles,
uch as fungi. Finally, there is a lack of knowledge as
o which assay (if any) predicts patients at greater risk
or delayed or incomplete immune recovery.
Strategy 2. Boost Global Immune Reconstitution.
everal molecules to enhance global immune recon-
titution have been tested in preclinical models, and
hase I and II clinical trials are now underway in
arious stages. These include keratinocyte growth fac-
or (KGF) [29-31], luteinizing hormone-releasing
ormone (LHRH) agonist [32], and interleukin (IL)-7
33,34]. Another molecule, IL-15, holds promise in
reclinical models [35,36]. Findings from these trials
ill become known within the next 2 to 3 years, at
hich time we environ a Phase III trial of the most
romising immunomodulatory molecule. Another ap-
roach to improve global immune reconstitution is to
void immunosuppression posttransplant. Addbacks
f certain cellular subsets selected to speed recovery
ay be part of such a strategy, but would be intimately
nvolved in considerations of GVHD prophylaxis.
Strategy 3. Enhance Pathogen-Speciﬁc Immunity.
everal clinical trials are underway to test vaccine
trategies for pertinent pathogens that are important
or HSCT. These include the protein-conjugate
neumococcal vaccine [37-39], inactivated VZV vac-
ine [37-40], and inactivated CMV vaccine [41].
hese are being tested in adults with ablative condi-
ioning regimens in allogeneic transplants using both
ibling and unrelated donors. Several anti-CMV
doptive immunotherapy studies are also now under-
ay. A Phase II study showed that the strategy of
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BMT CTN State of the Science Symposium 2007 1273rophylactic cytomegalovirus (CMV)-speciﬁc T cell
herapy resulted in a similar rate of CMV disease but
ecreased the need for antiviral drugs and was associ-
ted with less neutropenia. Questions remain regard-
ng the optimal composition and antigen speciﬁcity of
he cellular product, standardization of immune func-
ion assays, clinical endpoints, use of antivirals, and
ogistical issues as to the manufacturing of the cells for
arge multicenter studies under GMP conditions.
iscussion Summary
Numerous comments were made of the need for
eaching consensus on a standardized set of immune
ssays and timing of assessment before a therapeutic
rial could be launched. The importance of deﬁning
afety of candidate interventions in pilot studies was
mphasized.
OMMITTEE 5. LATE EFFECTS/QUALITY OF LIFE
urrent State of the Science
The BMT CTN has not conducted speciﬁc trials
n late effects or quality of life (QOL). However,
everal trials incorporate QOL measures as secondary
ndpoints. Please note that treatment of cGVHD is
ddressed by the GVHD committee.
rial 1. Educational Intervention to Improve
ealth Screening
Background and Hypothesis. Limited data in HSCT
urvivors suggest they are no more likely to undergo
reventive health procedures and engage in healthy be-
aviors than the general population despite a high inci-
ence of late adverse treatment effects, frequent contact
ith the medical system, and elevated rates of morbidity
nd mortality. We will test the hypothesis that an edu-
ational intervention targeted at patients and/or physi-
ians including structured reminders will improve com-
liance with recommendations for cancer screening,
ppropriate organ function testing, and screening for
sychosocial distress when compared to standard care.
Trial Design and Feasibility. We propose a Phase III
andomized trial to compare usual care to an inter-
ention that heightens attention to potential medical,
unctional, and psychosocial complications after
SCT [42,43]. To improve standardization, accessi-
ility, and generalizability, the intervention will be
omprised of mailed information and web-based ma-
erials and/or phone calls delivered after HSCT. The
tudy would use an intermediate endpoint, such as
atient self-reported screening rates, health behaviors,
nd detection and treatment of late effects, as surro-
ates for improving the health of survivors. Genera-
ion of pilot and feasibility data for the intervention
ould be required. srial 2. Stress Management to Improve Physical
nd Emotional Functioning
Background and Hypothesis. Many studies have doc-
mented deﬁcits in QOL after HSCT but few have
ocused on testing interventions to improve QOL and
unctioning. Data from single centers suggest that
xercise and stress management improves QOL and
unctional status in HSCT recipients [44-50]. We will
est the hypothesis that participation in an exercise
nd stress management program reduces fatigue and
tress and improves QOL in HSCT recipients.
Trial Design and Feasibility. We propose a Phase III
andomized trial to compare usual care to a stress
anagement intervention based upon exercise and
elaxation/imagery techniques. The primary end-
oints will be QOL and functional status. The advan-
ages of such a study are: (1) high patient interest in an
ntervention aimed at improving QOL, (2) lack of
ompeting studies, (3) abundant preliminary data to
upport conduct of a multicenter Phase III trial. Chal-
enges include: (1) standardization of the intervention,
2) infrastructure at each center to deliver the inter-
ention, (3) logistic difﬁculties associated with collec-
ion of patient-reported outcomes. Use of a self-ad-
inistered intervention would mitigate the ﬁrst 2
oncerns.
rial 3: Standardized Collection of
atient-Reported Outcomes
Background and Hypothesis. Several ongoing BMT
TN studies collect patient-reported outcomes in-
luding QOL and functional status. Lack of agree-
ent about the speciﬁc instruments, assessment
oints, data collection methods, and analysis plans
imit QOL comparisons across trials. We will test the
ypothesis that incorporation of a manageable set of
OL/symptom instruments across randomized trials
ill allow inter and intratrial comparisons.
Trial Design and Feasibility. Instruments will cap-
ure sociodemographic and work/school items for
oth pediatric and adult populations. Collection of
OL information prior to transplantation and at 1
nd 3 years after HSCT would mirror the recommen-
ations of the Stem Cell Transplant Outcomes Data-
ase (SCTOD). The core set of measurements should
ot require more than 10-15 minutes to complete.
ome trials will require additional instruments and/or
ime points to address speciﬁc scientiﬁc questions. An
n-line version of the core assessment would improve
ata quality and reduce long-term costs when used by
atients with Web access. Housing QOL data in a
eference database within the BMT CTN will facili-
ate cross/trial analysis. The major barrier to imple-
entation will be adequate infrastructure at individualites to collect high quality QOL data.
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J.L.M. Ferrara et al.1274iscussion Summary
Audience comments focused on the feasibility of
he proposed interventions, data collection, the valid-
ty of the instruments and expected effect sizes, a
otential placebo effect, anticipated difﬁculties with
issing data, and whether additional study is neces-
ary to know “best practices.” There was also discus-
ion about whether children could be included in the
roposed studies.
OMMITTEE 6. PEDIATRICS
urrent State of the Science
HSCTs in children and adolescents account for
0%-25% of all HSCTs performed in North Amer-
ca. Currently, more than 40% of unrelated donor
ransplants in children utilize UCB as the stem cell
ource (M. Eapen, personal communication). The
MT CTN, together with Children’s Oncology
roup (COG), is currently conducting a randomized
hase III trial testing whether the double cord blood
ransplants improve survival and engraftment and de-
reases the rate of leukemic relapse without increasing
he rate of GVHD compared to single cord blood
ransplants. BMT CTN 0601 is a Phase II trial of
onmyeloablative unrelated donor HSCT for chil-
ren with severe sickle cell disease. Two additional
reas of HSCT trials applicable to children could be
eveloped in the next additional 5 years.
rial 1. Reduced Intensity Conditioning (RIC) for
emophagocytic Lymphohistiocytosis (HLH)
Background and Hypothesis. Hemophagocytic disor-
ers are comprised primarily of HLH, but also include
-linked lymphoproliferative syndrome (XLP), Che-
iak-Higashi syndrome, and Griscelli syndrome. These
onmalignant syndromes are often fatal, and are char-
cterized by hyperproduction of inﬂammatory cyto-
ines such as tumor necrosis factor alpha (TNF). The
iagnosis of HLH can be established by genetic and
unctional testing. Allogeneic HSCT is the only cur-
tive option but early transplant-related mortality
TRM) of 35% is a major barrier to success [51]. We
ill test the hypothesis that RIC will result in im-
roved survival by decreased treatment-related mor-
ality without loss of efﬁcacy for patients with HLH.
Trial Design and Feasibility. We propose a deﬁni-
ive Phase II trial with a primary endpoint of day 100
ortality. Pilot data [52,53] suggest that an RIC reg-
men is safe and effective in children with nonmalig-
ant disorders, including HLH. Inhibition of TNF
uring transplant may be desirable both because TNF
s implicated in transplant-related complications and
s a speciﬁc mediator in HLH. In 2006, 26 transplants
or HLH were registered at the CIBMTR. A single
eference laboratory for HLH in North America pro- cides an opportunity to characterize the disease at diag-
osis. Accrual of 40-50 patients is feasible within 4 years.
rial 2. Post HSCT Immunomodulation for
ediatric Acute Lymphoblastic Leukemia
Background and Hypothesis. Leukemia relapse ac-
ounts for the majority of failures after transplant for
cute lymphoblastic leukemia (ALL) [54]. One possi-
le strategy is control of post-HSCT minimal residual
isease (MRD). The mTOR inhibitor sirolimus to
ontrol MRD [55,56] and MTX is highly synergistic
ith sirolimus in preclinical models of ALL. Alterna-
ive strategies would be the use of TLR7 and TLR9
gonists, which alter the immunogenicity of ALL
lasts as well as induce an immunologically mediated
ntileukemia response [57,58]. A TLR7 agonist (imi-
uimod) is currently under investigation for refractory
eukemia patients [59]. We will test the hypothesis
hat one of these agents will decrease leukemia relapse
hen used as maintenance therapy after HSCT.
Trial Design and Feasibility. Because the majority of
elapses occur in the ﬁrst post-HSCT year, the pri-
ary endpoint will be 1-year event-free survival.
aintenance therapy post-HSCT with a toll-like re-
eptor agonist will begin within several weeks of the
ransplant and continue for the 1 year. One or more of
hese agents mentioned above should be available for
hase II trials within the next 4 years. Collaboration
etween the COG and the BMT CTN will ensure
dequate accrual.
iscussion Summary
There was a high level of enthusiasm by all HSCT
hysicians as well as support by the pediatric HSCT
ommunity for the HLH proposal. Further prelimi-
ary studies were thought to be required to develop
mmune modulation after HSCT. Pediatricians also
trongly supported the prioritization of HSCT studies
n lysosomal disorders, severe combined immune de-
ciencies, and hemaglobinopathies, as funding be-
omes available.
OMMITTEE 7. LEUKEMIA
urrent State of the Science
Leukemia is the most common indication for
SCT. As HSCT outcomes improve, there is clinical
se of HSCT as early therapy for various leukemias.
ut new agents also have increased efﬁcacy, and there
re almost no comparisons of these therapeutic ap-
roaches. The committee selected from the following
rials a large number of potentially important ques-
ions based on their broad relevance, the existence of
ufﬁcient preliminary data to warrant rapid activation
f network-wide studies, and the likelihood of successful
ompletion. Trials are organized by type of leukemia.
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rial 1. A Prospective Trial of Allogeneic HSCT
nd Modern Chemotherapy for Adult Ph ALL in
irst CR
Background and Hypothesis. Prior to the availability
f imatinib and other BCR-ABL tyrosine kinase in-
ibitors, the outlook for patients with Ph ALL
reated with conventional chemotherapy was ex-
remely poor, and accordingly, allogeneic transplan-
ation was the treatment of choice. Recently, several
roups using imatinib in combination with conven-
ional chemotherapy have reported outcomes in Ph
LL that rival those obtained with allogeneic trans-
lantation [60-62]. Preliminary data suggest that the
ore potent tyrosine kinase inhibitor, dasatinib, can
e combined with intensive chemotherapy safely. We
ill test the hypothesis that modern chemotherapy
ncorporating a tyrosine kinase inhibitor will yield
isease-free survival (DFS) similar to that achieved
ith allogeneic HSCT.
Trial Design and Feasibility. We propose a Phase
II, “biologic assignment” design. Patients will be en-
ered at diagnosis and receive an allogeneic transplant
n ﬁrst CR if an appropriate donor is available, or be
reated with HyperCVAD  dasatinib. Because pa-
ient evaluation will begin at diagnosis, this trial would
e conducted in collaboration with cooperative
roups. If the outcome of such a combination is equiv-
lent to that achieved with allogeneic HSCT, then
llogeneic HSCT could be reserved for patients at
igh risk of relapse or who have molecular evidence of
RD.
rial 2. A Prospective Trial of Reduced Intensity
llogeneic HSCT for Patients with Ph ALL in
irst CR Aged 35-60 years
Background and Hypothesis. The recent MRC
KALL XII/ECOG E2993 trial demonstrated that
or patients with Ph ALL, HLA-matched sibling
llogeneic transplantation results in a statistically sig-
iﬁcant improvement in survival, when compared to
onventional chemotherapy [63]. This advantage was
educed in patients above age 35 because of an in-
rease in TRM. We will test the hypothesis that the
dvantages of allogeneic HSCT in Ph ALL in ﬁrst
emission in patients over age 35 can be improved
sing a less intensive preparative regimen.
Trial Design and Feasibility. We propose a Phase II
rial in which patients with Ph ALL, aged 35-60
ears with matched siblings or appropriately matched
nrelated donors will be treated with a transplant
egimen of melphalan plus ﬂudarabine. This question
an be approached in an upcoming intergroup ALL
tudy. mML
rial 1. A Prospective Trial of Allogeneic
ransplantation versus Chemotherapy for Adults
ith AML in First CR Aged > 60 years
Background and Hypothesis. The outcome for pa-
ients with AML over age 60 treated with conven-
ional chemotherapy is generally poor, with a median
FS of 7-9 months and fewer than 15% alive disease-
ree at 3 years [64]. Several groups have recently re-
orted encouraging results using RIC regimens for
his group of patients, including 3-year DFS rates of
4% for recipients of matched related transplants and
3% after matched unrelated transplantation [65].
here is a need to conﬁrm these results in a prospec-
ive trial in which patients achieving CR are treated
ith transplantation if a suitable donor is available and
hose without donors treated with chemotherapy. We
ill test the hypothesis that reduced intensity alloge-
eic transplantation from a matched sibling or unre-
ated donor will provide longer survival compared
ith chemotherapy.
Trial Design and Feasibility. If the advantage with
ransplantation persists, this would change the stan-
ard of therapy for this group of individuals. A large
rial of this type could only be performed in close
ollaboration with NCI cooperative groups. Repre-
entatives from all the groups have participated in this
ommittee and are enthusiastic about the proposal.
rial 2. A Prospective Randomized Trial of RIC
ersus Conventional Intensity Conditioning in
atients with AML Aged 35-60 years
Background and Hypothesis. RIC regimens in older
atients with AML in ﬁrst remission are associated
ith relapse rates not too dissimilar from those seen
ith more intensive regimens in younger patients.
hus, the conduct of a prospective randomized com-
arison of a conventional intensive preparative regi-
en with an RIC regimen in middle-aged (35-60)
atients with AML is warranted. We will test the
ypothesis that any increase in relapse rates caused by
reduction in the intensity of conditioning in patients
ged 35-60 years will be balanced by a reduction in
RM, leading to a safer and ultimately equally effec-
ive regimen.
Trial Design and Feasibility. Should equivalence be
een in the two approaches, this would both provide a
afer and equally effective approach for patients, and
ould also provide a platform onto which leukemia-
peciﬁc therapies might be more easily added.
rial 3. Unrelated Donor Transplantation versus
hemotherapy for High-Risk AML
Background and Hypothesis. A recent meta-analysis
f all studies published since 1995 that compare che-
otherapy with allogeneic transplantation from
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J.L.M. Ferrara et al.1276atched siblings for adults aged 17-60 years reported
statistically signiﬁcant survival advantage with allo-
eneic transplantation [1]. This advantage was partic-
larly evident for patients with high-risk disease, as
eﬁned by cytogenetics. Use of alternative donors for
his group of patients is unsettled, but single prospec-
ive trial suggests an advantage for unrelated donor
ransplantation [66]. We propose a prospective trial
omparing the results of unrelated allogeneic transplan-
ation with conventional chemotherapy in younger pa-
ients (aged  60 years) with high-risk AML in ﬁrst
emission.
Trial Design and Feasibility. The details of this trial
re discussed in more detail in the report of Commit-
ee 1.
HRONIC LYMPHOCYTIC LEUKEMIA (CLL)
rial 1. A Phase II Trial of Reduced Intensity
llogeneic Transplantation for Patients with very
igh-Risk CLL
Background and Hypothesis. Approximately 25% of
atients with CLL will have chromosomal abnormal-
ties involving 17p13.3 and 11q22–23. These patients
end to have a particularly aggressive form of CLL,
ith a higher likelihood of transformation to an ag-
ressive lymphoma and a shorter overall survival (OS)
67]. Preliminary results with reduced intensity allo-
eneic transplantation in patients with ﬂudarabine-
esistant CLL have yielded encouraging results [68].
hus, a question of considerable interest would be the
tility of reduced intensity allogeneic transplantation
pplied early in the course of patients with cytogenet-
cally deﬁned high-risk disease. We will test the hy-
othesis that reduced intensity allogeneic HSCT will
mprove survival compared to historical controls in
atients with very high-risk CLL.
Trial Design and Feasibility. Given the limited pre-
iminary data and the great variability of CLL pa-
ients, we acknowledge that a randomized trial is pre-
ature and would be difﬁcult to perform. However, a
hase II trial of this approach would be informative
nd of high interest.
HRONIC MYELOGENOUS LEUKEMIA (CML)
The use of HSCT in the treatment of CML is
ow largely limited to patients who have failed treat-
ent with tyrosine kinase inhibitors. Although a large
umber of questions exist about the appropriate use of
ransplantation in CML, including, for example, the
mportance of molecular monitoring to allow early
ransplant in patients developing tyrosine kinase resis-
ance, the committee was unable to identify a clinical
rial in CML with a high likelihood of successful tompletion because of small numbers of patients and
he rapid development of new drugs.
YELODYSPLASIA (MDS)
Patients with MDS, who are transplanted with
arlier stage disease (as determined, for example, by
nternational Prognostic Scoring System [IPSS]) tend
o have a superior outcome [69]. However, it is un-
nown whether attempts to improve the IPSS score
retransplant result in an overall clinical beneﬁt. The
ommittee recognized that a question of general in-
erest is the utility of DNA methyl-transferase inhib-
tor therapy prior to proceeding to an allogeneic
ransplant (for patients with intermediate-2/high-risk
DS) [69a]. However, concerns about the likelihood
f successfully completing such a study prevented its
nclusion on our high priority list.
iscussion Summary
High enthusiasm was expressed for all trials.
here was some concern expressed regarding the fea-
ibility of the AML trials. The audience appreciated
he thoughtful deliberations of the committee and was
specially enthusiastic about potential collaborations
etween the BMT CTN and the NCI cooperative
roups to ask these important questions regarding the
ole of HSCT as primary therapy for several leuke-
ias.
OMMITTEE 8. LYMPHOMA
urrent State of the Science
HSCT is a proved curative treatment modality for
any patients with non-Hodgkin lymphoma (NHL)
nd Hodgkin disease, but relapse after HSCT remains
he leading cause of treatment failure. The BMT
TN is exploring strategies to reduce the risk of
ymphoma relapse, including incorporation of novel
reatments such as radioimmunoconjugates to aug-
ent the conditioning regimen. Identiﬁcation of im-
ortant biologic characteristics to guide these thera-
ies or provide earlier recognition of high-risk
atients is central to these goals.
Strategy 1. Allogeneic nonmyeloablative condi-
ioning regimen is a recent advance in the ﬁeld of
SCT that has broadened its applicability. A growing
umber of published reports have demonstrated the
fﬁcacy of nonmyeloablative transplantation (NMT)
n NHL including in patients who had failed standard
herapy or relapsed after prior autologous HSCT
28,70]. Thus, the exact role and optimal timing of
MT is an unanswered question that warrants further
nvestigation. Phase II trials could initially best answer
hese questions. The lymphoma subtypes with dem-
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BMT CTN State of the Science Symposium 2007 1277nstrated sensitivity to a graft-versus-tumor (GVT)
ffect such as mantle cell lymphoma [71,72] and fol-
icular cell lymphoma [73] are subtypes in which
MT should be explored. A multicenter Phase II
tudy of NMT for relapsed follicular cell lymphoma is
n an advanced stage of protocol development. Diffuse
arge cell lymphoma (DLCL) is the most common
HL subtype, and more options are needed for pa-
ients with recurrent DLCL who fail to demonstrate
igniﬁcant response to salvage chemotherapy. Thus, a
rospective approach comparing autologous HSCT
ersus autologous followed by NMT could be consid-
red if sufﬁcient data existed to support the role of
utologous followed by NMT for high-risk DLCL
atients.
Strategy 2. Patients with T cell lymphomas typ-
cally respond to frontline therapy but relapse, com-
only leading to shortened survivals despite the use of
utologous HSCT as consolidation therapy in CRI or
s a salvage therapy [74]. These observations under-
core the need for investigation of allogeneic HSCT
n this lymphoma subtype, but progress has been lim-
ted partly because of the low incidence and the het-
rogeneity of histologies in this particular NHL sub-
ype. These problems could be addressed by the BMT
TN in a multi-institutional fashion.
Strategy 3. Demonstration of the role of autolo-
ous transplantation for the treatment of certain sub-
ets of NHL such as mantle cell lymphoma or T cell
ymphomas are attractive areas of study. For example,
randomized comparison between standard chemo-
herapy with HyperCVAD autologous HSCT could
e pursued for the upfront treatment of mantle cell
ymphoma.
iscussion Summary
The major goal of future studies is to validate the
ole of autologous transplantation in the treatment of
ubsets of patients and to explore allogeneic transplan-
ation for patients with high-risk disease. The biologic
asis of the immune response and potential target
ntigens is of critical importance. Compilation of tis-
ue samples for future immunologic analysis would be
ital in achieving these goals. Additionally, the grow-
ng evidence implicating B cells in the pathogenesis of
VHD and cGVHD [75] supports the investigation
f B cell depletion before, during, or after the condi-
ioning regimen in assessing GVHD risk. Obstacles
hat hinder accrual of lymphoma patients to HSCT
linical trials include the heterogeneity of the disease
nd the availability of numerous nontransplant op-
ions. Lack of deﬁnitive response criteria and variabil-
ty in intensity of NMT conditioning regimens are
dditional hurdles. Effectively harnessing the GVT
esponses with acceptable toxicity should be the inte- hral goal of these trials. The advent of prognostic
ndices such as the IPI [8], FLIPI [76,77], FDG-PET
canning to assess response, and gene expression pro-
ling [78] may further help identify which patients
ay most beneﬁt from HSCT.
OMMITTEE 9. MULTIPLE MYELOMA
urrent State of the Science
Although autologous HSCT has been shown to
eneﬁt patients with multiple myeloma (MM), the
vailability of new therapies has persuaded many pa-
ients and physicians that high-dose therapy (HDT)
as a limited role as consolidation. Overcoming this
arrier will require a concerted education effort. Sig-
iﬁcant knowledge gaps regarding the biology of my-
loma and its treatment also hamper the efforts of
eveloping rationale risk-tailored therapies.
rial 1. The Role of Continued HDT with
utologous HSCT for All Symptomatic Myeloma
atients
Background and Hypothesis. MM is the most com-
on indication for HDT with autologous HSCT
79]. The availability of new agents and combinations
ow result in CR and near CR rates of over 50% [80].
n this context, we will test the hypothesis that autol-
gous HSCT will provide a survival advantage when
sed as early consideration as therapy for MM.
Trial Design and Feasibility. We propose a Phase
II randomized trial for patients with newly diag-
osed MM of early consolidation with HDT versus
DT upon relapse. Lack of consensus regarding
ptimal induction therapy as well as strong patient
nd physician preferences makes this study difﬁcult
o conduct. However, many cooperative groups are
urrently exploring the issue of optimal induction
herapy for MM, and once these are concluded the
ole of consolidation therapy with ASCT can be
eexplored. The BMT CTN is collaborating with
COG and CALGB in a national trial to explore
he role of posttransplant consolidation. Once this
rial is concluded, we prepare to test the hypothesis
hat there is no beneﬁt of tandem transplantation
n the context of modern therapy for MM. This trial
ill randomize patients to receive 1 of 3 therapies
fter the ﬁrst transplant: second autologous HSCT;
cycles of combination therapy with bortezomib,
enalinomide, dexamethasone, or observation. All
atients will receive lenalinomide maintenance
herapy.
Strategy 1. The Role for Allografting in My-
loma. The results of the recently published Italian
tudy as well as the ongoing BMT CTN 0102 trial will
elp determine the role of allografting in MM [81].
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J.L.M. Ferrara et al.1278he lack of sibling donors in most patients and the
oxicity of this treatment modality will impede the use
f allografting as frontline treatment in most patients.
ecause disease relapse remains the single most im-
ortant cause of treatment failure in patients receiving
IC allografts for myeloma, allografting studies
hould focus on new graft-versus-myeloma targets,
ovel posttransplant strategies, as well as different
onditioning regimens. Currently, a CIBMTR pilot
rial of posttransplant lenalinomide maintenance is
eing designed and will begin later this year.
Strategy 2. The Use of CR as a Surrogate Marker
or Long-Term Survival and Disease Control. The
se of CR as an endpoint in MM trials is increasingly
ontroversial [82]. Prospective evaluations of new mo-
ecular markers for speciﬁc cytogenetic abnormalities
nd other plasma cell indicators need to be incorpo-
ated into future trials.
iscussion Summary
The SOSS participants felt that an early versus
ate transplant study was the most important question
o address and encouraged the group to explore the
dea again once an optimal induction treatment was
dentiﬁed. The participants also considered that con-
inued study of allogeneic transplantation with cura-
ive intent should be a priority, particularly in younger
atients or patients with high risk disease. Novel
ransplant strategies aimed at improving outcomes by
educing rates of relapse or severe cGVHD were also
riorities. Finally, there was a general consensus that
alidation of the new response criteria for myeloma
sing samples from the current BMT CTN trial
ould be an important addition to our fund of knowl-
dge.
OMMITTEE 10. NONMALIGNANT DISORDERS
urrent State of the Science
Nonmalignant but life-threatening hematologic
isorders such as AA, paroxysmal nocturnal hemoglo-
inuria, and thalassemia major have been treated with
llogeneic HSCT for decades. Recently, there is sig-
iﬁcant interest in autologous HSCT as a therapy that
ould eliminate an individual’s autoreactive lympho-
ytes in severe autoimmune disease such as systemic
upus erthamatosies (SLE), multiple sclerosis (MS),
nd inﬂammatory bowel disease. In addition, investi-
ators are exploring the potential of allogeneic HSCT
o treat these same autoimmune diseases.
rial 1. GVHD Prophylaxis Using Mesenchymal
ells (MSC) in Matched-Related Donor Allogeneic
ransplantation for Severe Aplastic Anemia
Background and Hypothesis. Allogeneic HSCT can
rovide long-term disease control and potential gure of nonmalignant diseases, including autoim-
une diseases [81,83-86]. The main limitation to the
pplication of allogeneic HSCT for the treatment of
onmalignant disorders is GVHD. MSC have immuno-
odulatory activity that may be beneﬁcial in prevent-
ng GVHD and may also have a role in healing dam-
ged tissue [87,88]. AA would be ideal as a model
isease for testing the potential of MSC to prevent
VHD. We will test the hypothesis that adminis-
ration of MSC will prevent GVHD and facilitate
issue repair after allogeneic HSCT for AA.
Trial Design and Feasibility. We propose a ran-
omized Phase II trial of MSC infusion after HLA
dentical sibling donor HSCT for severe AA in an
ttempt to reduce the incidence of aGVHD from
0% to 25%. MSCs will be derived from the sibling
onor, and serial determinations will document the
ersistence of donor-derived MSC in recipients.
he optimal pretransplant conditioning regimen
or AA (and unrelated donor HSCT) is currently
eing determined in the BMT CTN 0301 trial [89].
he proposed protocol would take advantage of the
xperiences from this trial and build on the existing
rotocol team’s experience. To limit the heteroge-
eity of MSCs, common standard operating proce-
ures (SOPs) will be developed and the cells pro-
uced by the NIH funded Production Assistance to
ell Therapy (PACT) facilities.
rial 2. CD 34 Selected Autologous HSCT for
evere Crohn’s Disease
Background and Hypothesis. Preliminary data sug-
est that Crohn’s disease may also be amenable to
herapy with autologous HSCT, which has shown
romise in controlling several autoimmune diseases
90-92]. The mechanism of disease control is pur-
orted to be through resetting of the patient’s im-
une system. Currently there are 3 national trials
upported by the NIAID of autologous HSCT in
atients with autoimmune diseases. Uncontrolled sin-
le-center data suggest efﬁcacy for autologous HSCT
n severe Crohn’s disease [93,94], and a multinational
rial is currently accruing patients in Europe. We will
est the hypothesis that autologous HSCT may result
n improved survival for poor prognosis inﬂammatory
owel disease.
Trial Design and Feasibility. We propose a random-
zed Phase II trial of autologous HSCT for therapy-
efractory Crohn’s disease using positively selected
D 34 peripheral blood progenitor cells (PBPC).
rimary endpoints will be DFS, with secondary end-
oints of OS, RRT, QOL, and disease. Crohn’s dis-
ase activity (CDA) will be measured by the CDA
ndex. Such an approach is currently being explored in
urope and the NIAID is very interested in this con-
ept. Mortality in severe Crohn’s disease is high, and
astrointestinal physicians would likely collaborate in
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BMT CTN State of the Science Symposium 2007 1279uch an effort. Appropriately designed, a U.S. trial
ould be complementary to the current European trial
ut with sufﬁcient commonality with regard to eligi-
ility and outcome measures to allow interstudy com-
arisons or potentially a pooled analysis.
iscussion Summary
During the discussion there was much enthusiasm
or the future potential of mesenchymal cells in the
rea of allogeneic transplantation and regenerative med-
cine, although at present, the participants thought that
he strategy was too early in development for a large
etwork trial. There was also concern that HLA
atched sibling donor transplants for AA may not be
he best setting for such an early study as the outcomes
re already very good despite GVHD and cGVHD.
here was more enthusiasm for autologous HSCT in
evere, refractory Crohn’s disease with vigorous dis-
ussion of key issues such as eligibility, the condition-
ng regimen, and the role of CD34 selection. There
as consensus to make preliminary enquiries of gas-
rointestinal physicians who currently manage such
atients to determine their willingness to partici-
ate in such a trial.
OMMITTEE 11. GENE AND CELL THERAPY
urrent State of the Science
Randomized trials are currently ongoing using
SC to treat aGVHD and Thymidine Kinase (TK)-
ransduced T cells to augment immune recovery and
reat relapse posttransplant. Global considerations
ith cell and gene therapy studies include multiple
egulatory issues, including IND requirements, pro-
uction of cells, clinical grade vectors and ancillary
eagents, and manufacture of centralized versus mul-
icenter cellular products. BMT CTN, in collabora-
ion with other NHLBI resources such as PACT, can
otentially support central administration, legal in-
emniﬁcation, clinical regulatory affairs, GMP vector
anufacturing, and cell processing to facilitate ad-
ancement of these approaches. Cell therapy studies
ay extend traditional HSCT applications, and the
MT CTN could create a cellular therapy committee
ith the goal of fostering research across multiple
ransplant and nontransplant disciplines.
Strategy 1. Immunotherapies. Although multivirus
peciﬁc CTLs have efﬁcacy, the current methodol-
gy using repeated stimulation with APC cells ex-
ressing viral antigens is too cumbersome to use in
ulticenter trials [95]. Similar approaches using
llodepleted T cells are still being optimized
96,97]. Alternative means of reconstituting antivi-
al immunity include rapid selection processes using
etramer selection or gamma-interferon capture, Put the former product has restricted speciﬁcity,
hereas the latter is limited by low yields. Another
ption is to evaluate banked allogeneic lines, which
ould be manufactured with the assistance of
ACT; a recent study showed activity of allogeneic
pstein-Barr virus (EBV)-speciﬁc CTL lines in pa-
ients with posttransplant lymphoma [98]. Trans-
ort of manufactured NK cell products has been
alidated, and thus a Minnesota regimen transfer-
ing haploidentical NK cells prior to a reduced
ntensity conditioning regimen may be ready for
ransfer to multicenter trials [99]. Tumor vaccine
pproaches using genetically modiﬁed cells have
lso shown activity posttransplant, and because a
ingle bank can be made, this approach could fea-
ibly be translated to BMT CTN. An alternative
ould be to develop a vaccination study using PR1
nd WT1 peptides [100].
Strategy 2. Gene Therapies. The administration of
onor lymphocyte infusions (DLI) post-HSCT is lim-
ted by the development of GVHD. Insertion of a
onditional “suicide” gene (eg, HSV-TK) into the T
ells prior to infusion allows them to be eliminated if
hey cause GVHD [101,102]. Multiple variations to
his approach (vector, gene, and timing) may affect
fﬁcacy and need to be tested in clinical trials. The
enes encoding the T cell receptors from antitumor
TL or chimeric molecules combining antibody ele-
ents that bind to tumor-associated antigens with
ntracellular signaling domains from T cell receptors
an be inserted into mature T cells or into hemato-
oietic stem cells to engineer T cells with speciﬁc
ntitumor activity. Initial studies are focused on CD19
s a tumor-associated antigen of B lymphoid malig-
ancies [103]. Several single-center trials of these ap-
roaches will open in the United States soon, but
mportant logistic and legal issues will need to be
esolved to move these studies from their single sites
f origin to multiple sites. There are also a number of
ingle-center studies exploring drug resistance gene
herapy, a technology that could be used in future
tudies to improve allogeneic transplantation strate-
ies.
Strategy 3. Mesenchymal Cells. The clinical appli-
ation most amendable to a multicenter study is the
se of MSCs to prevent/treat GVHD and/or to foster
ngraftment of hematopoietic stem cells [104,105].
lthough the European Group for Blood and Marrow
ransplant (EBMT) is currently conducting such
tudies, the MSCs are processed locally raising the
ossibility of heterogeneity of the MSC preparations
mong different institutions. A trial using homoge-
ous MSC population would advance the ﬁeld, for
xample, in SAA where stable engraftment is a “cure,”
nd GVHD/GVL is of no therapeutic value. Further,
ACT could produce the MSCs for all sites using a
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ree of fetal calf serum (FCS).
iscussion Summary
The audience agreed that more preliminary sin-
le-center data are needed on the gene transfer ap-
roaches discussed before multicenter trials could be
onsidered. They also felt that the setting of matched
ibling transplant for nonmalignant disease may not
e the best scenario to evaluate mesenchymal cells.
arly relapse (eg, detectable minimal residual disease
ost-HSCT) was suggested as a good setting to assess
he use of DLI with suicide gene for GVHD recall.
here was support for a Phase II trial of allogeneic
losely HLA-matched virus-speciﬁc CTLs to treat
denoviral infections.
OMMITTEE 12. CLINICAL TRIAL DESIGN
urrent State of the Science
A major impediment to successful implementation
nd completion of clinical trials in HSCT (and other
elds) is the amount of time and effort required to
ctivate studies in individual institutions, to ensure
ompliance with often complex protocols and to com-
lete and submit data for large numbers of required
bservations [106]. Funding for trials is often inade-
uate for these activities. The HSCT community
hould simplify HSCT protocols as much as possible
nd minimize the work required to participate, con-
idering each of the following:
. protocols should allow the use of institutional stan-
dards for nonessential selection criteria and clinical
management practices;
. the number and frequency of required observations
should be limited to the minimum necessary to
assess primary and secondary outcomes;
. in deciding which secondary outcomes to assess,
the potential value of the information obtained
should be carefully weighed against the cost of
obtaining it;
. duplication of data collection should be avoided,
and further consensus should be developed for
HSCT-related common data elements to be used
by all investigators planning clinical trials. Proto-
col-speciﬁc data collection instruments should
build on the consensus datasets developed by CIB-
MTR and EBMT. These datasets have already
been adopted by Foundation for Accreditation of
Cellular Therapy (FACT) and the congressionally
mandated SCTOD;
. information systems that can interface with local
and other network databases should be developed
so that clinical data entered locally for institutional
purposes can be used to comply with protocol-
mandated data submission (“enter once, use often” aprinciple); data submitted to the SCTOD should
be shared with organizations doing clinical trials;
. central institutional review board (IRB) review
(rather than individual IRB review) should be
encouraged;
. improved accounting models should be developed
to address the actual expense of conducting trials;
. in developing trials, The BMT CTN should in-
crease involvement of individuals/centers beyond
the Steering Committee and Core Centers to en-
sure that issues of cost, feasibility, and relevance are
better addressed and to enhance participation.
The use of combined Phase II-III designs would
inimize the time spent activating trials. When Phase
I and III trials are conducted separately, the Phase II
rial is usually not randomized and compares an ex-
erimental therapy to a historical rate that may be
ither unknown or subject to selection bias [106-110];
nrolled patients cannot be used in a subsequent Phase
II comparison. Additionally, the Phase III trial must
o through a completely separate protocol develop-
ent, review, and activation process. A seamless tran-
ition between Phase II and Phase III could increase
fﬁciency by decreasing the total number of patients
equired and by avoiding the need for development,
eview and activation of a second protocol [111-115].
n the combined Phase II-III approach, a randomized
hase II stage employs a “screening” rule based on an
nbiased comparison of the treatment and control
rms; these criteria can include the planned primary
ndpoint for the Phase III portion of the trial, but may
onsider other endpoints. If screening criteria are met,
he study moves into Phase III. Patients enrolled in
he Phase II stage may be included in the Phase III
omparison, possibly reducing the total sample size.
ne disadvantage is that more patients are needed for
he Phase II stage of such trials than for single-arm
hase II trials. In selecting a design, it is important to
onsider (1) the reliability of the estimated historical
ate, and (2) the amount of experience with the new
reatment, because Phase II randomization may be
ore acceptable for a treatment with more extensive
rior experience. A variation of the Phase II/III design
ses group sequential methods in a Phase III study to
ccommodate early stopping for efﬁcacy or futility.
iscussion Summary
The audience was in general agreement with the
ecommendations, including simplifying protocols,
roadening eligibility criteria, and permitting institu-
ional standards for supportive care to the extent pos-
ible. It was felt that this would increase accrual and
ecrease the need for multiple amendments. The in-
reasing complexity of the IRB and informed consent
rocess and the need to simplify data reporting were
lso emphasized.
CB
y
1
t
c
w
l
a
p
w
c
1
1
o
t
s
w
i
b
g
C
C
J
W
D
E
J
R
J
E
C
J
D
S
M
R
R
S
D
P
D
C
S
S
M
P
J
G
K
C
F
R
R
S
R
H
C
A
M
C
S
B
R
N
S
K
R
BMT CTN State of the Science Symposium 2007 1281ONCLUSIONS
The SOSS fully met expectations to frame the
MT CTN scientiﬁc agenda for the next several
ears. Following the presentation and discussion of all
2 committees, the Chairs, together with several of
he international panel of experts, reviewed the dis-
ussions and made recommendations. High priority
as given only to those protocols with sufﬁcient pre-
iminary data to begin protocol design and studies that
waited completion of ongoing trials were given lower
riority. Of the 20 trials proposed, high enthusiasm
as generally expressed for the following 11 proto-
ols:
1. GVHD: Phase II trial of calcineurin-free regi-
mens in patients with high risk cGVHD.
2. QOL: Phase III comparison of peritransplant
stress management interventions.
3. MM: Phase III comparison of tandem transplant
versus consolidation therapy with bortezomib,
lenalinomide, dexamethasone, versus immediate
maintenance therapy with lenalinoimide in pa-
tients receiving 1 autotransplant of VRD as con-
solidation therapy for MM.
4. AML: Phase III comparison of chemotherapy
versus unrelated donor in patients with high-risk
AML in CR1.
5. AML: Phase III comparison of full intensity con-
ditioning versus RIC in allogeneic HSCT recipi-
ents with AML aged 30-60 years.
6. ALL: Phase III comparison of chemotherapy 
dasatinib versus allogeneic HSCT in patients with
Ph ALL.
7. CLL: Phase II trial of reduced-intensity alloge-
neic HSCT in patients with very high-risk CLL.
8. Lymphoma: Phase II trial of reduced intensity
allogeneic HSCT as primary therapy for T cell
lymphoma.
9. HLH: Phase II trial of reduced intensity alloge-
neic HSCT in children with HLH.
0. Nonmalignant diseases: Phase II trial of autol-
ogous HSCT for refractory Crohn’s disease.
1. Cell therapy: Phase II trial of HLA-matched,
viral-speciﬁc CTLs to treat adenoviral infections.
The symposium leadership also unanimously rec-
mmended the formation of a Biomarkers Committee
hat would consider appropriate standardization of
ample banks and potential processing across all net-
ork protocols. The search for biomarkers is proceed-
ng in many other diseases and the BMT CTN will
eneﬁt from discussion and interchange with those
roups on a regular basis.
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